Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Atara Biotherap 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 USA

www.atarabio.com P: 805-623-4211

Description:

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.

Key Statistics

Overview:

Market Capitalization, $K 83,527
Enterprise Value, $K 57,537
Shares Outstanding, K 119,359
Annual Sales, $ 8,570 K
Annual Net Income, $ -276,130 K
Last Quarter Sales, $ 4,250 K
Last Quarter Net Income, $ -60,450 K
EBIT, $ -276,000 K
EBITDA, $ -270,380 K
60-Month Beta 0.69
% of Insider Shareholders 4.50%
% of Institutional Shareholders 70.90%
Float, K 113,988
% Float 95.50%
Short Volume Ratio 0.33

Growth:

1-Year Return -74.36%
3-Year Return -95.02%
5-Year Return -97.98%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 50.47%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.56 on 03/28/24
Latest Earnings Date 05/13/24
Earnings Per Share ttm -2.62
EPS Growth vs. Prev Qtr 15.15%
EPS Growth vs. Prev Year 22.22%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ATRA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -122.34%
Profit Margin % -3,222.05%
Debt/Equity 0.00
Price/Sales 9.95
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.97
Interest Coverage -51.19
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar